Sam Brusco, Associate Editor02.09.24
Biotronik has introduced the Micro Rx catheter, a rapid exchange microcatheter to enhance guidewire support during percutaneous coronary interventions (PCI).
The device is manufactured by Netherlands-based IMDS (Interventional Medical Device Solutions) and exclusively distributed by Biotronik. It marks the fourth IMDS product that Biotronik has brought to the U.S.
The Micro Rx catheter features a reinforced distal shaft with a core wire between two layers of braids. This allows optimal push transfer and a tapered tip with a very small leading edge for high force of penetration, according to the companies. It also touts a Proximal-End-Stop that allows integrating a guide extension catheter for further support.
It addresses the intricacies of navigating through difficult vascular anatomies like tortuous vessels and highly stenosed lesions. Without the need for trapping, the catheter aims to minimize vascular trauma risk and lower the time patients spend in the cath lab environment. It can allows non-chronic total occlusion (CTO) operators to successfully treat more complex lesions, the companies said.
The Micro Rx catheter is now available in the U.S., and will be released in Canada in March 2024.
"IMDS has invested its expertise and dedication into the development of the Micro Rx catheter, with a specific focus on alleviating challenges in PCI," said Biotronik USA president Ryan Walters. "This has resulted in a state-of-the-art solution, benefiting both physicians and the patients. We are proud to bring this innovation to the U.S. market."
In January, the company celebrated the milestone of 100,000 DX ICDs, which allow direct atrial sensing for AFib.
The device is manufactured by Netherlands-based IMDS (Interventional Medical Device Solutions) and exclusively distributed by Biotronik. It marks the fourth IMDS product that Biotronik has brought to the U.S.
The Micro Rx catheter features a reinforced distal shaft with a core wire between two layers of braids. This allows optimal push transfer and a tapered tip with a very small leading edge for high force of penetration, according to the companies. It also touts a Proximal-End-Stop that allows integrating a guide extension catheter for further support.
It addresses the intricacies of navigating through difficult vascular anatomies like tortuous vessels and highly stenosed lesions. Without the need for trapping, the catheter aims to minimize vascular trauma risk and lower the time patients spend in the cath lab environment. It can allows non-chronic total occlusion (CTO) operators to successfully treat more complex lesions, the companies said.
The Micro Rx catheter is now available in the U.S., and will be released in Canada in March 2024.
"IMDS has invested its expertise and dedication into the development of the Micro Rx catheter, with a specific focus on alleviating challenges in PCI," said Biotronik USA president Ryan Walters. "This has resulted in a state-of-the-art solution, benefiting both physicians and the patients. We are proud to bring this innovation to the U.S. market."
In January, the company celebrated the milestone of 100,000 DX ICDs, which allow direct atrial sensing for AFib.